Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: SOPHiA GENETICS SA

Market Cap 440M 385M 355M 332M 622M 41.61B 628M 4.23B 1.64B 20.42B 1.65B 1.61B 71.02B P/E 2026 *
-5.88x
P/E 2027 * -7.68x
Enterprise Value 440M 385M 355M 332M 622M 41.61B 628M 4.23B 1.64B 20.42B 1.65B 1.61B 71.02B EV / Sales 2026 *
4.71x
EV / Sales 2027 * 3.91x
Free-Float
76.47%
Yield 2026 *
-
Yield 2027 * -
1 day-0.43%
1 week+11.48%
Current month+8.88%
1 month+8.88%
3 months+7.37%
6 months+17.68%
Current year+20.10%
1 week 4.24
Extreme 4.24
4.74
1 month 4.06
Extreme 4.06
4.74
Current year 3.46
Extreme 3.46
4.82
1 year 3.34
Extreme 3.34
4.82
3 years 2.08
Extreme 2.08
5.1
5 years 2.08
Extreme 2.08
5.1
10 years 2.08
Extreme 2.08
5.1
Manager TitleAgeSince
Chief Executive Officer 47 31/12/2010
Director of Finance/CFO 64 04/11/2024
President 46 04/11/2024
Director TitleAgeSince
Chairman 47 21/06/2026
Director/Board Member 57 31/05/2014
Chairman 61 31/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%+11.48% - - 449M
-0.09%-4.00%-45.32%-24.43% 24.9B
+1.06%+6.49%-36.91%+151.97% 12.66B
-0.94%-9.21%-12.62%+51.24% 5.57B
+0.59%+1.81% - - 2.9B
+9.66%+28.35% - - 1.86B
-0.95%+2.25%+38.00%-45.37% 1.78B
-2.88%-1.20%-20.91% - 1.31B
-0.58%-3.10%-32.02%-61.09% 792M
+0.29%-5.27%-33.67%+240.85% 744M
Average +0.73%+1.70%-20.49%+52.20% 5.83B
Weighted average by Cap. +1.11%-0.93%-35.10%+35.54%

Financials

2026 *2027 *
Net sales 93.4M 81.74M 75.53M 70.5M 132M 8.84B 133M 898M 349M 4.34B 351M 343M 15.09B 112M 98.35M 90.88M 84.82M 159M 10.64B 161M 1.08B 420M 5.22B 422M 413M 18.16B
Net income -64.65M -56.58M -52.28M -48.8M -91.5M -6.12B -92.38M -622M -242M -3B -243M -237M -10.45B -50.72M -44.39M -41.02M -38.29M -71.79M -4.8B -72.48M -488M -190M -2.36B -190M -186M -8.2B
Net Debt - -
Logo SOPHiA GENETICS SA
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Employees
415
Date Price Change
22/06/26 4.660 -0.43%
19/06/26 4.680 0.00%
18/06/26 4.680 +3.08%
17/06/26 4.540 +7.08%
16/06/26 4.240 -0.93%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.340USD
Average target price
8.000USD
Spread / Average Target
+49.81%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!